Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

First International Summit on Interventional Pharmacoeconomics

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Bivalent CAR T-Cell Therapy Shows No Delayed Toxicity and Promising Survival in Recurrent Glioblastoma

Claudia Henschke, PhD, MD Finding Lung Cancer in Time

Starting Surveillance Colonoscopy After High-Risk Adenoma Removal When Is the Right Time

Evolving Strategies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

AI Model Based on Facial Image Analysis Estimates Biological Age and Mortality Risk in Patients With Cancer